CN118119614A - 6-(环丙烷甲酰胺基)-4-((2-甲氧基-3-(1-甲基-1H-1,2,4-三唑-3-基)苯基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺的晶型 - Google Patents

6-(环丙烷甲酰胺基)-4-((2-甲氧基-3-(1-甲基-1H-1,2,4-三唑-3-基)苯基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺的晶型 Download PDF

Info

Publication number
CN118119614A
CN118119614A CN202280068807.1A CN202280068807A CN118119614A CN 118119614 A CN118119614 A CN 118119614A CN 202280068807 A CN202280068807 A CN 202280068807A CN 118119614 A CN118119614 A CN 118119614A
Authority
CN
China
Prior art keywords
pxrd
crystalline form
pattern
methyl
room temperature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280068807.1A
Other languages
English (en)
Chinese (zh)
Inventor
C·魏
T·沙托克戈登
J·奥赫兰
T·威利福德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN118119614A publication Critical patent/CN118119614A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280068807.1A 2021-08-20 2022-08-19 6-(环丙烷甲酰胺基)-4-((2-甲氧基-3-(1-甲基-1H-1,2,4-三唑-3-基)苯基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺的晶型 Pending CN118119614A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163235635P 2021-08-20 2021-08-20
US63/235,635 2021-08-20
PCT/US2022/040884 WO2023023322A1 (en) 2021-08-20 2022-08-19 Crystal forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide

Publications (1)

Publication Number Publication Date
CN118119614A true CN118119614A (zh) 2024-05-31

Family

ID=83283223

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280068807.1A Pending CN118119614A (zh) 2021-08-20 2022-08-19 6-(环丙烷甲酰胺基)-4-((2-甲氧基-3-(1-甲基-1H-1,2,4-三唑-3-基)苯基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺的晶型

Country Status (7)

Country Link
US (1) US20240368130A1 (https=)
EP (1) EP4387968B1 (https=)
JP (1) JP2024529763A (https=)
KR (1) KR20240050380A (https=)
CN (1) CN118119614A (https=)
ES (1) ES3062193T3 (https=)
WO (1) WO2023023322A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024241347A1 (en) * 2023-05-25 2024-11-28 Msn Laboratories Private Limited, R&D Center Novel polymorphs of 6-(cyclopropanecarbonylamido)-4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-n-(trideuteriomethyl)pyridazine-3-carboxamide
ES3059443A1 (es) * 2024-09-17 2026-03-20 Moehs Iberica Sl Forma solida de 6-(ciclopropanocarboxamido)-4-((2-metoxi-3-(1-metil-1h-1,2,4-triazol-3-il)fenil)amino)piridazine-3-carboxilato de metilo o una sal del mismo, procedimiento para su preparacion y su uso en la sintesis de deucravacitinib

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3495358T (lt) * 2012-11-08 2022-05-25 Bristol-Myers Squibb Company Amidais pakeisti heterocikliniai junginiai, naudingi kaip il-12, il-23 ir (arba) ifn alfa atsako moduliatoriai
JP7113023B2 (ja) 2017-03-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー ６－（シクロプロパンアミド）－４－（（２－メトキシ－３－（１－メチル－１ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－ｎ－（メチル－ｄ３）ピリダジン－３－カルボキシアミドの製造方法
KR102848769B1 (ko) 2018-05-31 2025-08-20 브리스톨-마이어스 스큅 컴퍼니 6-(시클로프로판카르복스아미도)-4-((2-메톡시-3-(1-메틸-1h-1,2,4-트리아졸-3-일)페닐)아미노)-n-(메틸-d3) 피리다진-3-카르복스아미드의 결정질 형태
US12570637B2 (en) 2019-06-12 2026-03-10 Bristol-Myers Squibb Company Crystalline salt forms 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyld3) pyridazine-3-carboxamide
KR20230137962A (ko) * 2021-01-29 2023-10-05 브리스톨-마이어스 스큅 컴퍼니 6-(시클로프로판카르복스아미도)-4-((2-메톡시-3-(1-메틸-1h-1,2,4-트리아졸-3-일)페닐)아미노)-n-(메틸-d3)피리다진-3-카르복스아미드의 결정 형태
CN117377667A (zh) * 2021-03-29 2024-01-09 百时美施贵宝公司 6-(环丙烷甲酰胺基)-4-((2-甲氧基-3-(1-甲基-1H-1,2,4-三唑-3-基)苯基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺的晶型

Also Published As

Publication number Publication date
EP4387968A1 (en) 2024-06-26
EP4387968B1 (en) 2025-11-12
KR20240050380A (ko) 2024-04-18
WO2023023322A1 (en) 2023-02-23
US20240368130A1 (en) 2024-11-07
JP2024529763A (ja) 2024-08-08
ES3062193T3 (en) 2026-04-09

Similar Documents

Publication Publication Date Title
US12545665B2 (en) Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide
CN118994118A (zh) 化合物的结晶形式
EP4284796B1 (en) Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide
CN117377667A (zh) 6-(环丙烷甲酰胺基)-4-((2-甲氧基-3-(1-甲基-1H-1,2,4-三唑-3-基)苯基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺的晶型
CN118119614A (zh) 6-(环丙烷甲酰胺基)-4-((2-甲氧基-3-(1-甲基-1H-1,2,4-三唑-3-基)苯基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺的晶型
WO2025106462A1 (en) 2-(4-(2-(7, 8-dimethyl-[1,2,4]triazolo[1,5-a] pyridin-6-yl)-3-isopropyl-1h-indol-5-yl)piperidin-1-yl)acetamide salt and crystalline forms thereof
AU2024380732A1 (en) 2-(4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl- 1h-indol-5-yl)piperidin-1-yl)acetamide and crystalline forms thereof
EA044397B1 (ru) КРИСТАЛЛИЧЕСКАЯ ФОРМА 6-(ЦИКЛОПРОПАНКАРБОКСАМИДО)-4-((2-МЕТОКСИ-3-(1-МЕТИЛ-1H-1,2,4-ТРИАЗОЛ-3-ИЛ)ФЕНИЛ)АМИНО)-N-(МЕТИЛ-d3)ПИРИДАЗИН-3-КАРБОКСАМИДА

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination